Yescarta
What Yescarta is used for
Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Advanced therapy: a gene, cell or tissue-engineered medicine.
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Yescarta
- Active substance
- axicabtagene ciloleucel
- Disease area
- Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX70
- Marketing authorisation holder
- Kite Pharma EU B.V.
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yescarta used for?
Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.
What is the active substance in Yescarta?
Yescarta contains axicabtagene ciloleucel.
Who makes Yescarta?
The EU marketing authorisation holder is Kite Pharma EU B.V..
Is Yescarta an orphan medicine?
Yes. Yescarta is designated an orphan medicine in the EU, for a rare disease (Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU